Dana–Farber Cancer Institute

Updated on Nov 28, 2024

Edit

Comment

Care system Private Affiliated university Harvard Medical School Number of beds 27		Funding Non-profit hospital Founder Sidney Farber

Location 450 Brookline Avenue, Boston, Massachusetts, US Hospital type Teaching and Specialist Standards NCI-designated Cancer Center Address 450 Brookline Ave, Boston, MA 02215, USA CEO Laurie Glimcher (Oct 2016–) Hours Closed now Wednesday8:30AM–5PMThursday8:30AM–5PMFriday8:30AM–5PMSaturdayClosedSundayClosedMonday8:30AM–5PMTuesday8:30AM–5PM Similar Pulsipher Michael A MD, Dana Farber Cancer Inst, Boston Medical Center, Jennifer Chan - MD - MPH Profiles LinkedIn Facebook Instagram Google+ YouTube

Dana–Farber Cancer Institute is a comprehensive cancer treatment and research center in Boston, Massachusetts. It is a principal teaching affiliate of Harvard Medical School, and a founding member of Dana–Farber/Harvard Cancer Center, a Comprehensive Cancer Center designated by the National Cancer Institute.

Overview

Dana-Farber employs more than 4,274 full-time and part-time people, 467 faculty, and has annual gross revenues of about $1,086,638,000. There are more than 299,202 adult and pediatric patient visits a year, and it is involved in more than 700 clinical trials. It is internationally known for its research and clinical excellence. Expertscape ranks its programs in aplastic anemia and multiple myeloma as best in the world. It has been also ranked the fourth best cancer hospital in the United States by U.S. News & World Report. Dana-Farber is a member of the Multiple Myeloma Research Consortium.

In addition to being a principal teaching affiliate of Harvard Medical School, Dana-Farber is also a federally designated Center for AIDS Research, and a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC), a federally designated Comprehensive Cancer Center. Providing advanced training in cancer treatment and research for an international faculty, Dana-Farber conducts community-based programs in cancer prevention, detection, and control in New England, and maintains joint programs with other Boston institutions, including Brigham and Women's Hospital, Boston Children's Hospital, and Massachusetts General Hospital.

Dana-Farber is supported by the National Cancer Institute, the National Institute of Allergy and Infectious Diseases, and private foundations and individuals contributions. The Jimmy Fund is the principal charity of the Institute named for one of its child patients. The Boston Red Sox adopted the Jimmy Fund as its official charity in 1953 and continues to prominently sponsor the charity.

Laurie H. Glimcher, MD is President / CEO of Dana–Farber Cancer Institute/Jimmy Fund. In 2015, Forbes listed the charity as the 37th biggest in the U.S.

History

1947 - Sidney Farber, MD, founded the Children's Cancer Research Foundation.

1969 - The Institute officially expanded its programs to include patients of all ages.

1974 - It became known as the Sidney Farber Cancer Institute in honor of its founder.

1983 - The support of the Charles A. Dana Foundation was acknowledged by incorporating Dana's name.

Breakthroughs

Dana-Farber has a long history of breakthrough discoveries in cancer care and research.

1947: Sidney Farber leads a team of researchers who are the first in the world to attain temporary remissions of acute lymphocytic leukemia, the most common cancer in children, using aminopterin. This, and another antifolate drug, methotrexate used by Dr. Farber, were discovered and supplied by Dr. Yellapragada Subbarow, Director, Research at Lederle Co. at Pearl River, NY.

1954: Farber and his colleagues achieve the first remissions of Wilms' tumor, a common form of childhood cancer, and boost cure rates from 40 percent to 85 percent.

1976: Researchers at the Sidney Farber Cancer Center (now Dana-Farber) develop a new treatment for acute myelogenous leukemia that produces the first complete remissions of the disease in up to half of all patients.

1978: Institute investigators develop combination chemotherapy for soft-tissue sarcomas resulting in a 50-percent response rate.

1982: Dana-Farber researchers develop and apply the CA-125 blood test for ovarian cancer. They also are among the first to suspect a relationship between the retrovirus that causes human T-cell leukemia (HTLV-1) and that which causes AIDS (HIV-1).

1991: Dana-Farber investigators help introduce the use of naturally occurring growth hormones following high-dose chemotherapy, making bone marrow transplantation safer and more effective.

1993: Dana-Farber investigators discover the gene that increases the risk for a common type of colon cancer. The MSH2 gene and later the MLH1 gene (also by DFCI investigators) are linked to hereditary nonpolyposis colorectal cancer (HNPCC).

1996: Institute researchers dramatically advance the understanding of how HIV, the virus that causes AIDS, replicates and infects healthy cells. Science magazine heralds this discovery as its "Breakthrough of the Year".

1998: A drug called imatinib (Gleevec), the early work for which was done at Dana-Farber, achieves striking success in many patients with chronic myelogenous leukemia.

1999: Working with colleagues at other hospitals, Dana-Farber scientists begin the first human studies of endostatin, one of a new generation of compounds that arrest or shrink tumors by shutting off their blood supply.

2002: Dana-Farber researchers find that Gleevec, a targeted therapy that achieved striking success against chronic myelogenous leukemia, can shrink and even eliminate tumors in some patients with a rare and otherwise incurable digestive-tract cancer called gastrointestinal stromal tumor.

2003: Scientists at Dana-Farber and the Whitehead Institute find a gene "signature" in several types of tumors that suggests they are likely to spread to other parts of the body, potentially leading to tests for determining whether tumors have the potential to metastasize.

2005: Dana-Farber scientists report that the drug gefitinib (Iressa) produces dramatic benefits in non-small cell lung cancer patients who carry an abnormal version of a key protein, a potentially life-saving discovery for tens of thousands of patients around the world every year.

Patient care

Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) is a collaboration between Dana–Farber Cancer Institute and Brigham and Women's Hospital to care for adults with cancer. Dana-Farber provides outpatient services, while inpatient care is provided by Brigham and Women's Hospital. DF/BWCC cares for adult patients in more than a dozen specialized treatment centers. This coordinated arrangement makes it possible for many people to see all of their specialists in a single visit.

Boston Children's Cancer and Blood Disorders Center is a more than 60-year-old partnership between Boston Children's Hospital and Dana–Farber Cancer Institute that delivers comprehensive care to children with and survivors of all types of childhood cancers.

They also work with several other local New England organizations that share a similar vision, such as Take a Swing at Cancer, Angel's Hope, Childhood Cancer Lifeline of New Hampshire and Andrew's Helpful Hands.

References

Dana–Farber Cancer Institute Wikipedia

(Text) CC BY-SA

Contents

Overview

History

Breakthroughs

Patient care

References